17.6 USD
+0.02 (+0.12%)
PRTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. While PRTC seems to be doing ok healthwise, there are quite some concerns on its profitability. PRTC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PRTC has reported negative net income.
In the past year PRTC has reported a negative cash flow from operations.
In multiple years PRTC reported negative net income over the last 5 years.
In the past 5 years PRTC always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 9.16%, PRTC belongs to the best of the industry, outperforming 93.58% of the companies in the same industry.
Looking at the Return On Equity, with a value of 13.48%, PRTC belongs to the top of the industry, outperforming 94.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROIC | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRTC has a Profit Margin of 792.96%. This is amongst the best in the industry. PRTC outperforms 99.25% of its industry peers.
PRTC's Profit Margin has declined in the last couple of years.
PRTC does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRTC has been reduced compared to 1 year ago.
PRTC has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, PRTC has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.73, we must say that PRTC is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.73, PRTC is doing good in the industry, outperforming 66.23% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that PRTC is not too dependend on debt financing.
PRTC has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.73 |
ROIC/WACCN/A
WACC8.58%
2.3 Liquidity
PRTC has a Current Ratio of 8.49. This indicates that PRTC is financially healthy and has no problem in meeting its short term obligations.
PRTC has a better Current ratio (8.49) than 76.23% of its industry peers.
PRTC has a Quick Ratio of 8.49. This indicates that PRTC is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.49, PRTC is doing good in the industry, outperforming 76.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 168.34% over the past year.
The earnings per share for PRTC have been decreasing by -32.49% on average. This is quite bad
The Revenue has grown by 1265.60% in the past year. This is a very strong growth!
The Revenue for PRTC have been decreasing by -13.22% on average. This is quite bad
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
3.2 Future
PRTC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.77% yearly.
PRTC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 223.14% yearly.
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PRTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as PRTC's earnings are expected to decrease with -17.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
5. Dividend
5.1 Amount
No dividends for PRTC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PRTC (1/9/2026, 8:18:33 PM)
17.6
+0.02 (+0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.59%
Inst Owner Change0%
Ins Owners4.86%
Ins Owner ChangeN/A
Market Cap425.36M
Revenue(TTM)6.39M
Net Income(TTM)50.68M
Analysts84
Price Target67.76 (285%)
Short Float %0.03%
Short Ratio1.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.27%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 66.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.13 | ||
| P/tB | 1.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.27
EYN/A
EPS(NY)-6.52
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0.26
BVpS15.56
TBVpS15.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 | ||
| Altman-Z | 1.73 |
F-Score7
WACC8.58%
ROIC/WACCN/A
Cap/Depr(3y)9.91%
Cap/Depr(5y)37.78%
Cap/Sales(3y)7.17%
Cap/Sales(5y)20.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.77%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
EBIT growth 1Y13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.57%
EBIT Next 3Y-5.38%
EBIT Next 5Y3.12%
FCF growth 1Y36.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.98%
OCF growth 3YN/A
OCF growth 5YN/A
PURETECH HEALTH PLC - ADR / PRTC FAQ
Can you provide the ChartMill fundamental rating for PURETECH HEALTH PLC - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to PRTC.
Can you provide the valuation status for PURETECH HEALTH PLC - ADR?
ChartMill assigns a valuation rating of 0 / 10 to PURETECH HEALTH PLC - ADR (PRTC). This can be considered as Overvalued.
Can you provide the profitability details for PURETECH HEALTH PLC - ADR?
PURETECH HEALTH PLC - ADR (PRTC) has a profitability rating of 3 / 10.
What is the financial health of PURETECH HEALTH PLC - ADR (PRTC) stock?
The financial health rating of PURETECH HEALTH PLC - ADR (PRTC) is 5 / 10.